Bank of New York Mellon’s Kailera Therapeutics KLRA Stock Holding History

Bank of New York Mellon’s Portfolio KLRA Stock Details KLRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.05M	Buy	+138,399	New	+$3.04M	﹤0.01%	2711

Other funds holding KLRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon's KLRA Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 138,399 shares worth $3.05M. The stake represents ﹤0.01% of the portfolio and ranks #2711 among its holdings.

29 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

Bank of New York Mellon held 138,399 shares of Kailera Therapeutics worth $3.05M as of Q2 2026.
Kailera Therapeutics was a new Bank of New York Mellon position in Q2 2026.
Kailera Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2711 holding.
29 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.